Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodevelopmental Disorder Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CHD8 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CHD8 Recombinant Protein (ATPase Domain / Chromodomain) High purity (>95%), Endotoxin controlled. Sequence Verified. |
View CHD8 Products |
| Gene Delivery | CHD8 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and rescue assays. |
View CHD8 Products |
| Benchmark Ab | Anti-CHD8 Recombinant Antibody High-affinity positive control for IP, ChIP, and Western Blot. |
View CHD8 Products |
| Validator | CHD8 siRNA Set For target knockdown and specificity validation. |
View CHD8 Products |
| Related Target A | CHD4 Subfamily homolog; critical for off-target selectivity screening. |
View CHD4 Products |
| Related Target B | Androgen Receptor (AR) Functional partner; CHD8 modulates AR-mediated transcription in prostate cancer. |
View AR Products |
| Related Target C | Beta-Catenin (CTNNB1) Wnt pathway effector; CHD8 interacts with Wnt signaling in development and oncology. |
View CTNNB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against CHD family homologs | Active CHD4 and CHD7 homolog panel proteins strictly verified by mass spectrometry. |
| Large multi-domain protein expression | Specific functional domain truncations (ATPase, Chromodomain) optimized for high solubility and assay compatibility. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and recombinant controls included. |
| False Positives in HTS | Validated siRNA sets included for orthogonal target knockdown verification. |
Live CHD8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CHD8 therapeutics is intensifying, with major players shifting focus from traditional academic target validation to targeted small-molecule inhibition and PROTAC-mediated degradation. As first-generation chromatin remodeling therapies reach the clinic, the next wave of R&D is targeting CHD8's specific oncogenic roles in hormone-dependent cancers and its haploinsufficiency in neurodevelopmental disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Epigenetic Biotech Startups, Academic Consortia | Prostate Cancer, Breast Cancer | ATPase Activity Assay (Need soluble, active recombinant CHD8 domains) |
| PROTAC / Degraders | Targeted Protein Degradation (TPD) Pioneers | Advanced Solid Tumors, Therapy-Resistant Cancers | Ternary Complex Formation (Need biotinylated/tagged CHD8 and CHD4 counter-screens) |
| Gene Therapy / mRNA | Neurodevelopmental Therapeutics Firms | CHD8-Syndrome (Autism Spectrum Disorder) | Functional Rescue & Expression (Need high-titer Lentiviral ORF delivery) |